Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma

Steven Aller, Andrada Roxana Popescu, Sudha Rao, Elaine R Morgan, Yasmin C Gosiengfiao*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Metastatic medullary thyroid carcinoma (MTC) is an aggressive malignancy with an extremely poor prognosis. Currently no effective conventional systemic therapies exist to treat pediatric MTC. We describe an adolescent female with newly diagnosed MEN2B syndrome who presented with advanced stage metastatic MTC and demonstrated a partial transient response to sorafenib monotherapy. This clinical result supports further research into the use of sorafenib in the treatment of pediatric MTC.

Original languageEnglish (US)
Pages (from-to)98-100
Number of pages3
JournalPediatric Blood and Cancer
Volume58
Issue number1
DOIs
StatePublished - Jan 1 2012

Keywords

  • MEN2B syndrome
  • Metastatic medullary thyroid carcinoma
  • Sorafenib

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Fingerprint Dive into the research topics of 'Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma'. Together they form a unique fingerprint.

Cite this